ROCHE HOLDINGS AG GENUSSCHEINE NPV

ISIN: CH0012032048 WKN: 1203204 Asset Class: Stock



Company Profile

Roche Holding AG is a research healthcare company. It operates through the Pharmaceuticals and Diagnostics segments. The Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Financial figures, Fiscal year: from 01.01. to 31.12.

	202	23	20	22	202	21
Financial figures	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets I	Liabilities and equity
Current assets	33,446,000,000		33,816,000,000		35,627,000,000	
Common stock capital		107,000,000		107,000,000		160,000,000
Fixed assets	57,022,000,000		54,335,000,000		56,690,000,000	
Equity capital of a company		33,263,000,000		32,015,000,000		28,345,000,000
Cash and cash equivalents	5,376,000,000		4,991,000,000		6,850,000,000	
Accrued liabilities		5,438,000,000		5,672,000,000		7,545,000,000
Other assets	-		-		-	
Current liabilities		24,824,000,000		27,239,000,000		38,416,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		32,381,000,000		28,897,000,000		25,556,000,000
Different income		-		-		-
Other liabilities		259,000,000		298,000,000		282,000,000
Total assets	90,468,000,000	90,468,000,000	88,151,000,000	88,151,000,000	92,317,000,000	92,317,000,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	103,605	103,613	100,920
Equity ratio	41.13%	40.88%	34.88%
Debt-equity ratio	143.12%	144.61%	186.69%

Others

	2023	2022	2021
Tax Expense Rate	12.20%	17.08%	14.16%

ROCHE HOLDINGS AG GENUSSCHEINE NPV

ISIN: CH0012032048 WKN: 1203204 Asset Class: Stoc

Income statement

	2023	2022	2021
Turnover	58,716,000,000	63,281,000,000	62,801,000,000
Net income	11,498,000,000	12,421,000,000	13,930,000,000
EBIT	15,573,907,500	17,697,480,000	18,494,992,500
Operating income before taxes	14,111,000,000	16,368,000,000	17,400,000,000
Cash Flow	15,493,000,000	17,890,000,000	20,569,000,000
Net interest income	-828,000,000	-608,000,000	-341,000,000
Research and development expenses	13,231,000,000	14,050,000,000	13,707,000,000
Income taxes	1,721,000,000	2,796,000,000	2,463,000,000
Result from investments in subsidaries, associates and other	-32,000,000	-41,000,000	-2,000,000
Revenues per employee	590,815	636,700	648,732

Board of Directors

Manage and the analysis is tractice to a soul
Member of the administrative board
Chairman of the administrative boar

Members of Management Board

Thomas Schinecker	Chairman of Managing Board	
Alan Hippe	Member of Executive Committee	
Aviv Regev	Member of Executive Committee	
Dr. Hans Clevers	Member of Executive Committee	
James H. Sabry	Member of Executive Committee	
Levi Garraway	Member of Executive Committee	
Barbara Schädler	Member of Executive Committee	
Claudia Böckstiegel	Member of Executive Committee	
Cristina A. Wilbur	Member of Executive Committee	
Matt Sause	Member of Executive Committee	
Silke Hörnstein	Member of Executive Committee	
Teresa Graham	Member of Executive Committee	